Exiqon Launches ExiLERATE LNA™ qPCR Product Portfolio
Complete the form below to unlock access to ALL audio articles.
The ExiLERATE LNA™ qPCR portfolio complements the miRCURY LNA™ PCR product offering for miRNA amplification– a product that was rated best performing among 12 different platforms in a comparative study published in Nature Methods 2014 Aug;11(8):809-15.
ExiLERATE LNA™ qPCR portfolio includes a suite of products supporting a complete sample-to-answer solution including sample isolation, cDNA generation and reagents needed for real-time PCR amplification and detection. The portfolio includes a number of pre-validated endogenous controls and a validated assay-design pipeline to support custom assays. Focus has been on developing a highly sensitive and specific system with particular focus on the cDNA synthesis. Proprietary technology enables cDNA synthesis at elevated temperatures thereby overcoming challenging secondary structures and high GC content.
Modern RNA discovery begins with Next Generation Sequencing which has revealed a significantly more complex transcriptome than originally anticipated. This drives a growing demand for custom qPCR assays to validate new transcripts or variants of transcripts. To accommodate this demand, Exiqon has developed an assay design engine for effortless design of custom assays.
“We are excited to continuously expand our product offering within qPCR to address customer needs. This product offering completes our portfolio and we are now able to support LNA™ enhanced qPCR detection of any RNA, including short and long RNAs.” said Senior Vice President Sales & Marketing, Dr. Henrik M. Pfundheller
The ExiLERATE LNA™ qPCR products are compatible with all major real-time PCR instruments.
